OR WAIT null SECS
March 01, 2023
Key challenges posed to autologous and allogeneic treatments could be resolved by in-vivo CAR-T gene therapies.
February 24, 2023
AbbVie and Capsida have expanded their existing collaboration to advance three new gene therapy programs.
February 07, 2023
CBM’s plasmid manufacturing offering is designed to provide phase-appropriate plasmids on demand for companies working on cell and gene therapies.
December 14, 2022
Emmes’ new facility is designed to support clients conducting cell and gene therapy research worldwide.
October 28, 2022
The newly formed partnership between CSafe and BioLife will expand cold chain supply chain solutions for the cell and gene therapy market.
October 25, 2022
Vibha Jawa, executive director at Bristol Myers Squibb, and Luke Schenck, principal scientist at Merck & Com, discuss cell & gene therapies and co-processed APIs respectively.
October 16, 2022
Significant improvements have been developed to tackle the challenges in viral vector manufacturing at each stage.
October 12, 2022
CBER maps modernization plan to handle surge in research and applications.
October 05, 2022
Production of viral vectors requires a holistic view of the product, including its manufacturing process and its ultimate end use.
October 02, 2022
Whether biologic manufacturers decide to outsource or develop products internally, the quality of a CDMO partnership is critical to success, especially for cell and gene therapy products.